Review Board


  • Dominic Wells, Professor in Translational Medicine, Royal Veterinary College, London
  • Thomas Rando, Professor of Neurology and Neurological Sciences, Stanford University School of Medicine; Director, Glenn Laboratories for the Biology of Aging, Stanford University; Chief, Neurology Service, VA Palo Alto Health Care System

Board of Reviewers

  • Derek Blake, Professor of Neuroscience, Department of Psychological Medicine and Neurology, Cardiff University School of Medicine
  • Susan C.Brown, Reader in Translational Medicine, Department of Veterinary Basic Science, Royal Veterinary College, Royal College Street, Camden Town
  • Gillian Butler-Browne, Research Director, Institute of Myology, Platform for Human and Cell Culture, Paris, France
  • Rachelle Crosbie, Associate Professor, Department of Integrative Biology and Physiology, UCLA
  • Kay Davies, Head of Department of Physiology, Anatomy and Genetics, University of Oxford
  • Annamaria De Luca, Dipartimento di Farmacia, Università degli Studi di Bari, Italy
  • George Dickson, Director, Institute of Biomedical & Life Sciences, South West London Academic Network
  • Dongsheng Duan, Margaret Proctor Mulligan Professor in Medical Research, University of Missouri
  • James Dowling, Departments of Pediatrics and Molecular Genetics, University of Toronto
  • James Ervasti, Professor, Biochemistry, Molecular Biology, and Biophysics, University of Minnesota
  • Kenneth Fischbeck, Neurogenetics Branch, National Institute of Neurological Disorders and Stroke
  • Stanley Froehner, Professor and Chair, Physiology and Biophysics, University of Washington
  • Miranda Grounds, Professor, Anatomy and Human Biology, The University of Western Australia
  • Jane Hewitt, Professor of Mammalian Genetics, Faculty of Medicine & Health Sciences, University of Nottingham
  • Se Jin Lee, Professor, Johns Hopkins University School of Medicine, Molecular Biology & Genetics
  • Paul Martin, Associate Professor, Department of Pediatrics and Children’s Research Institute, Ohio State University
  • Uli Mayer, Biomedical Research Centre, School of Biological Sciences, University of East Anglia, Norwich, UK
  • Elizabeth McNally, Professor, Department of Medicine, Director, Institute for Cardiovascular Research. The University of Chicago
  • Eugenio Mercuri, Professor of Pediatric Neurology, Università Cattolica del Sacro Cuore
  • Jenny Morgan, Reader in Cell Biology,  The Dubowitz Neuromuscular Centre, UCL Institute of Child Health
  • Vincenzo Nigro, Professore Ordinario di Genetica Medica presso la Facoltà di Medicina e Chirurgia della Seconda Università degli Studi di Napoli
  • Jill Rafael-Fortney, Associate Professor, Cardiovascular Medicine, Molecular & Cellular Biochemistry, Physiology and Cell Biology, Ohio State University
  • Melissa Spencer, Associate Professor, Neurology, Director, Center for Duchenne Muscular Dystrophy Center, UCLA
  • Derek Stemple, Wellcome Trust Sanger Institute
  • Volker Straub, Harold Macmillan Professor of Medicine, Institute of Human Genetics, University of Newcastle upon Tyne
  • Shin’ichi Takeda, Department of Molecular Therapy, National Center of Neurology and Psychology, National Institute of Neuroscience
  • Steve Winder, Professor, Molecular Cell Biology, The University of Sheffield
  • Peter Zammit, Reader, Muscle Cell Biology, Randall Division of Cell and Molecular Biophysics, King’s College London

Funding and Competing Interests Statements

  • PLOS Currents: Muscular Dystrophy is produced with support from PPMD.  Editorial responsibility for the content in PLOS Currents: Muscular Dystrophy rests entirely with PLOS and the Editors.
  • Dominic Wells has received funding from MRC, EPSRC, BBSRC, EU FP6, Wellcome Trust, UK Department of Health, BHF, MDC, MDA, AFM, Big Lottery Fund, Action Medical Research, Parent Project Muscular Dystrophy, Duchenne Parent Project (Netherlands), ICE Consortium and GM Trust (now Duchenne Research Fund). He has also received funding from Proximagen. He is a member of the TREAT-NMD Advisory Committee on Therapeutics (TACT) and was Chair from 2012-2015. He is a member of the Scientific Advisory Board for Akashi Therapeutics, a member of the Medical Research Committee for Muscular Dystrophy UK, a member of the Gene and Cell Therapy Commission for AFM and a member of the Telethon Scientific Committee (Italy).
  • Thomas Rando has received funding (all from the USA unless otherwise noted) from the National Institutes of Health, the Department of Veterans Affairs, the Glenn Foundation for Medical Research, the Muscular Dystrophy Association, the American Federation for Aging Research, the Duchenne Parent Project (Netherlands), the Jain Foundation, the Association Française contre les Myopathies (France), the Ellison Medical Foundation, and the California Institute of Regenerative Medicine. He is on the Scientific Advisory Board for Fate Therapeutics and has served as a consultant for the following corporations: Asklepios Biopharmaceutical, FivePrime, Affymax, Rinat Neuroscience, and Cytokinetics. He is on the Scientific Advisory Board for the Parent Project Muscular Dystrophy (Netherlands), InStem (Department of Biotechnology, India), Fondzione Telethon (Italy), The Stem Cell Therapeutic Research Institute (Kyungpook National University, Daegu City, Korea), and CureDuchenne (USA)